| CASE REPORT |
|
| Year : 2020 | Volume
: 9
| Issue : 1 | Page : 38 |
|
|
Schizophrenia and macroprolactinoma: Is there a deep link?
Atefeh Bamarinejad1, Shidrokh Nasiri1, Fatemeh Bamarinejad1, Rezvan Salehidoost1, Elahe Zare-Farashbandi2
1 Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Clinical Informationist Research Group, Health Information Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Correspondence Address:
Dr. Rezvan Salehidoost
Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan
Iran
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/abr.abr_96_20
|
|
|
Prolactinomas are the most common type of functional pituitary tumors. Dopamine agonists is the most important drugs used in prolactinoma,have antagonistic effect with antipsychotic drugs used in schizophrenia. Conversely, dopamine antagonist drugs increase prolactin in patients with simultaneous schizophrenia. In the present case, we report a 29-year-old single male with schizophrenia who treated for 8 years with risperidone and presented with macroprolactinoma. Iatrogenic hyperprolactinemia is a well-known side effect of dopamine antagonist drugs for treatment in a patient with schizophrenia. On the other hand, it appears these drugs have the other side effects, such as drug- induced prolactinoma or boost growth.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
